ResearchSafe

KPV (Lysine-Proline-Valine Tripeptide)

Category: Healing & Recovery. Status: Research compound.

A tripeptide derived from alpha-MSH with potent anti-inflammatory properties. Shows promise for gut inflammation, skin conditions, and immune modulation without melanogenic effects.

How it works

Inhibits NF-kB signaling pathway, reduces pro-inflammatory cytokine production (TNF-α, IL-6), and modulates immune cell activation.

Key facts

  • Molecular weight: 342.43 Da
  • Half-life: ~2-3 hours
  • Bioavailability: ~60-70% oral; higher subcutaneous
  • Storage: Lyophilized: -20°C. Reconstituted: 2-8°C for up to 21 days.

Dosing overview

  • Typical dose: 200-500 mcg per dose
  • Frequency: 1-2x daily
  • Duration: 4-8 weeks
  • Route: Oral, topical, or subcutaneous

Protocol notes

  • Gut/inflammation goals: 200-500 mcg orally 1-2x daily, often on an empty stomach.
  • Skin/topical use: applied in a cream or as a localized subcutaneous dose.
  • Commonly paired with BPC-157 for gut-healing stacks.

Reported benefits

  • Potent anti-inflammatory
  • Gut inflammation reduction
  • Skin condition improvement
  • Immune modulation

Possible side effects

  • Mild drowsiness
  • Injection site reaction
  • Transient flushing

Research

  • KPV anti-inflammatory effects in colitis models (2021): Significantly reduced colonic inflammation and improved histological scores in IBD animal models.
  • Alpha-MSH derived peptides in skin inflammation (2019): Demonstrated reduction in inflammatory markers without melanotropic activity.

Compare KPV

Community discussions about KPV

Research and educational reference only. Not medical advice.